The role of asymmetric dimethylarginine (ADMA) and leptin in hypertensive patients

Basit Öğe Kaydı
dc.contributor.authorAtamer, A.
dc.contributor.authorIlhan, N.
dc.contributor.authorKocylgit, Y.
dc.contributor.authorToprak, G.
dc.contributor.authorOzbay, M.
dc.contributor.authorCelik, Y.
dc.date.accessioned2024-04-24T17:14:42Z
dc.date.available2024-04-24T17:14:42Z
dc.date.issued2008
dc.departmentDicle Üniversitesien_US
dc.description76th Congress of the European-Atherosclerosis-Society/15th Paavo Nurmi Symposium -- JUN 10-13, 2007 -- Univ Helsinki, Helsinki, FINLANDen_US
dc.description.abstractWe investigated the role of leptin and asymmetric dimethylarginine (ADMA) in uncomplicated hypertension. We also investigated their relationship with insulin resistance and serum levels of several metabolic parameters, including homocysteine, lipoprotein(a) and malondialdehyde (MDA). A total of 34 untreated newly-diagnosed hypertensive patients (seven men and 27 women; mean age, 57.4 +/- 10.1 years) and 38 normotensive healthy subjects (20 men and 18 women; mean age, 55.9 +/- 8.7 years) were studied prospectively. Serum leptin, homocysteine, lipoprotein(a), MDA and insulin resistance (HOMA-IR) were significantly higher in hypertensive patients compared with normotensive subjects. There were no significant differences in ADMA, insulin-like growth factor-1 and insulin-like growth factor binding protein-3 between the two groups. No correlation was found between serum ADMA and leptin levels. Our findings suggest that high serum leptin and homocysteine levels, oxidative stress and insulin resistance may be important risk factors for atherosclerosis among patients with uncomplicated hypertension.en_US
dc.description.sponsorshipEuropean Atherosclerosis Socen_US
dc.identifier.doi10.1177/147323000803600108
dc.identifier.endpage62en_US
dc.identifier.issn0300-0605
dc.identifier.issn1473-2300
dc.identifier.issue1en_US
dc.identifier.pmid18230268
dc.identifier.scopus2-s2.0-39149096877
dc.identifier.scopusqualityQ2
dc.identifier.startpage54en_US
dc.identifier.urihttps://doi.org/10.1177/147323000803600108
dc.identifier.urihttps://hdl.handle.net/11468/18151
dc.identifier.volume36en_US
dc.identifier.wosWOS:000253171700008
dc.identifier.wosqualityQ4
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.language.isoenen_US
dc.publisherSage Publications Ltden_US
dc.relation.ispartofJournal of International Medical Research
dc.relation.publicationcategoryKonferans Öğesi - Uluslararası - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectHypertensionen_US
dc.subjectLeptinen_US
dc.subjectLipoproteinen_US
dc.subjectInsulin Resistanceen_US
dc.subjectAsymmetric Dimethylarginine (Adma)en_US
dc.subjectMalondialdehyde (Mda)en_US
dc.titleThe role of asymmetric dimethylarginine (ADMA) and leptin in hypertensive patientsen_US
dc.titleThe role of asymmetric dimethylarginine (ADMA) and leptin in hypertensive patients
dc.typeConference Objecten_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu